Glenmark launches COVID-19 drug after DCGI nod 

Glenmark launches COVID-19 drug after DCGI nod 

Glenmark launches COVID-19 drug after DCGI nod 

Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The Mumbai-based drug firm on Friday received manufacturing and marketing approval from the Drugs Controller General of India ( DCGI).

Banner Ad

The drug will be available as a 200mg tablet at Maximum retail price of Rs 3,500 for a strip of 34 tablets. It will be available at hospitals and chemist shops and will be sold under medical prescription. At the moment the drug will be under restricted use, which means it can be consumed only under doctors guidance and supervision. People without prescription cannot buy it. 

Glenmark is the first company to come out with an oral antiviral drug for mild and moderate COVID-19 treatment. Favipiravir has been used in Russia, Japan and China to treat such patients and has been proved successful. 

            Glenmark launches COVID-19 drug after DCGI nod 

 

 

read more :

Telangana Intermediate results 2020
Telangana Intermediate results 2020

No more lockdowns, only unlocking

Coronavirus cases in Telangana – 19-06-2020 – charan news
Coronavirus cases in Telangana – 19-06-2020 – charan news

4 thoughts on “Glenmark launches COVID-19 drug after DCGI nod ”

Leave a Reply

Your email address will not be published. Required fields are marked *